Acrivon Therapeutics, Inc Common Stock
Price & Volume
Stats
See moreOpen | $1.50 |
Previous Close | $1.52 |
Day Range | $1.43-$1.52 |
52W Range | $1.05-$3.56 |
Market Cap | $58.8M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.02 |
News
See moreYahoo Finance • 3 months ago
3 Promising Penny Stocks With Market Caps Over $70M
Yahoo Finance • 4 months ago
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Yahoo Finance • 5 months ago
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
Yahoo Finance • 6 months ago
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
About
CEO | Dr. Peter Blume-Jensen M.D., Ph.D. |
CFO | Dr. Adam D. Levy M.B.A., Ph.D. |
Address | 480 Arsenal Way, Watertown, MA, United States, 02472 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 75 |
